Clinical Trial

A Phase Ib Study of RC148 as Monotherapy or Combination for Locally Advanced or Metastatic NSCLC

Active, Not Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This study will evaluate the efficacy, safety, pharmacokinetics and immunogenicity of RC148 injection as a single agent or in combination for the treatment of locally advanced or metastatic non-small cell lung cancer
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2025-03-12; most recent amendment 2026-03-04.
Status change: Recruiting → Active, Not Recruiting 2026-03-04
Status change: Not Yet Recruiting → Recruiting 2025-03-21
Trial Details
NCT Number NCT06883630
Lead Sponsor RemeGen Co., Ltd.
Conditions Non-Small Cell Lung Cancer
Enrollment 121 participants
Start Date 2025-03-13
Primary Completion 2026-08-31 (estimated)
Study Completion 2027-07-31 (estimated)
Updated on ClinicalTrials.gov 2026-03-05